A COMPARISON OF TAU AND 14-3-3 PROTEIN IN THE DIAGNOSIS OF CREUTZFELDT-JAKOB DISEASE
Andre Karch, Inga Zerr, Göttingen, Germany: Hamlin et al. 1 compared validities of 2 commonly used CSF tests for sporadic Creutzfeldt-Jakob disease (sCJD)-14-3-3 and total tau-and presented results contrary to previous studies. [1] [2] [3] [4] The present study is restricted to autopsy-confirmed cases, which seems reasonable, since neuropathology is the diagnostic gold standard in sCJD. However, using only autopsy-confirmed cases can also cause severe selection bias in a prospective setting, given that these tests are frequently requested in potentially treatable conditions. 2, 3 In the present study, clinicians were given results of 14-3-3 but not tau tests during the patient's lifetime. Autopsies were obtained in fewer than 10% of all initially referred patients. Thereby, decision about initiation of postmortem autopsy was directly dependent on 14-3-3 but not tau results. It seems a fair assumption that patients with CJD and negative 14-3-3 as well as patients without CJD and positive 14-3-3 were more likely to be autopsied than patients with consistent clinical history and 14-3-3 test results. Thereby, specificity and sensitivity of 14-3-3 are underestimated in this study design, which could explain differences in 14-3-3 validity when compared to previous studies. A final decision on test accuracy of 14-3-3 and total tau needs careful assessment in a prospective, multicenter study using standardized protocols for laboratory, clinical, and pathologic data.
